HIV lipoatrophy

HIV lipoatrophy

A subset of lipodystrophy that is liable to complicate prolonged multidrug antiretroviral therapy for HIV infection. There is peripheral breakdown of subcutaneous fat and central fat accumulation associated with type 2 diabetes. The effect is thought to be due to the use of nucleoside-analogue reverse-transcriptase inhibitors and HIV-PROTEASE INHIBITORS.
Mentioned in ?
References in periodicals archive ?
switch to TDF on limb fat, mitochondrial function, inflammation and bone mineral density in HIV lipoatrophy. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, 2010;342.
No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: A randomized trial.
"Adipocytes", "preadipocytes", "ADSC's" (adipose-derived stromal cells), "niche", scaffold, cell-cell interaction, blood circulating factors, paracrine factors, cell-matrix interaction, neurotransmitters, are key terms and, in the same time, key elements involved in regenerative surgery using fat transplant, leading to healing processes in facial HIV lipoatrophy. This novel type of closed surgery requires harvesting of the fat from the excessive deposits, which is then slowly centrifuged and transplanted with very fine instruments.
HIV lipoatrophy and decreased body mass index account for a major part of the decrease in bone mineral density among patients with HIV.
Switching stavudine or zidovudine to abacavir for HIV lipoatrophy: A randomized, controlled, open-label, multicentre, 24-week study.
Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.
Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices.